



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/848,948	05/04/2001	Samir M. Hanash	A31909-PCT USA	8499	
38485	7590 06/06/2005		EXAMINER		
ARENT FOX PLLC			RAWLINGS, STEPHEN L		
1675 BROADWAY NEW YORK, NY 10019			ART UNIT	PAPER NUMBER	
			1642		
		DATE MAILED: 06/06/2005			

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	
09/848,948	HANASH ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1642	

Before the Filing of an Appeal Brief	<u> </u>				
Before the Filling of all Appeal Brief	Examiner	Art Unit			
	Stephen L. Rawlings, Ph.D.	1642			
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress		
THE REPLY FILED 09 May 2005 FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR A	LLOWANCE.			
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:					
a) The period for reply expires 3 months from the mailing date of					
b) Light The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO					
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).				
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL					
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).					
<u>AMENDMENTS</u>					
3. The proposed amendment(s) filed after a final rejection,			because		
(a) They raise new issues that would require further co		TE below);			
(b) They raise the issue of new matter (see NOTE belo	•				
(c) ☐ They are not deemed to place the application in being appeal; and/or	tter form for appeal by materially re	educing or simplifying	, the issues for		
(d) They present additional claims without canceling a	corresponding number of finally re	jected claims.			
NOTE: (See 37 CFR 1.116 and 41.33(a)).					
4. The amendments are not in compliance with 37 CFR 1.1		ompliant Amendment	(PTOL-324).		
5. Applicant's reply has overcome the following rejection(s					
6. Newly proposed or amended claim(s) would be a	illowable if submitted in a separate	, timely filed amendm	ent canceling		
the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a)	☐ will not be entered or b) ☑ w	vill he entered and an	explanation of		
how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		in be entered and an	explanation of		
Claim(s) allowed:					
Claim(s) objected to: Claim(s) rejected: <u>1-5,14 and 16-18</u> .					
Claim(s) rejected: 1-3,14 and 10-10. Claim(s) withdrawn from consideration: 6-13 and 19-32.					
AFFIDAVIT OR OTHER EVIDENCE					
8. The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).					
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	ils to provide a		
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	entry is below or attac	:hed.		
The request for reconsideration has been considered by See Continuation Sheet.	it does NOT place the application i	n condition for allowa	nce because:		
12. ☑ Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s). 20031010			
12 D Others		\-/- ==== 			

13. Other: _

LARRY R. HELMS, PH.D



Continuation of 5. Applicant's reply has overcome the following rejection(s): The "written description" rejection set forth in section 5 of the preceding Office action; and the rejection under 35 U.S.C. 102(b) in section 7 of the preceding Office action.

Continuation of 11. Although the amendment has been entered, the amendment fails to obviate the remaining rejections of record. Applicant's arguments have been carefully considered but not found persuasive. With regard to the rejections under 35 U.S.C. 102(a) or 103(a) set forth in sections 6 or 9 of the preceding Office action, claim 1, for example, recites the step of detecting at least one S100 protein and the prior art teaches an antibody that binds to the heterodimer of S100-A9 and S100-A8. This antibody is used to detect at least one S100 protein selected from the group consisting of S100-A7 and S100-A8. The prior art teaches that the presence of the S100 protein in a biological sample acquired from a subject detected using the antibody is indicative of lung cancer in the subject Regarding the rejection set forth in section 8 of the preceding Office action, the prior art, again, teaches an antibody that binds an S100 protein, and claim 14 is drawn to a kit comprising an anti-S100 antibody. Regarding the grounds of rejection set forth in sections 10 and 11, Applicant has again remarked that a terminal disclaimer will be filed; however, as yet, none has been..

2